European Clinical Respiratory Journal最新文献

{"title":"Defined daily dose definition in medication adherence assessment in asthma.","authors":"Päivi Saukkosalmi,&nbsp;Hannu Kankaanranta,&nbsp;Iida Vähätalo,&nbsp;Lauri Sillanmäki,&nbsp;Markku Sumanen","doi":"10.1080/20018525.2023.2207335","DOIUrl":"https://doi.org/10.1080/20018525.2023.2207335","url":null,"abstract":"<p><p>Adherence to inhaled corticosteroids (ICS) has been described as poor. In adherence studies, if the actual prescribed dosing is not available, generic defined daily doses (DDD) are applied instead when assessing adherence. We evaluated asthma patients' adherence in a large prospective follow-up survey. We also analysed whether World Health Organization (WHO) and Global Initiative for Asthma (GINA) reference doses give different results. The current study was cross-sectional and included respondents attending to HeSSup follow-up questionnaire in 2012. Altogether 1,141 of 12,854 adult participants answered positively to the question about having asthma. According to the Finnish Social Insurance Institutions' medication register, 686 of them had purchased ICS medication during 2011. DDDs for ICS by WHO as well as medium doses from GINA report were used as reference doses to evaluate adherence. To estimate adherence to ICS, the proportion of days covered (PDC) over one year was calculated for every patient. If the lower limit of GINA medium ICS dose was used as a reference, 65% of the patients were adherent (PDC ≥ 80%). Use of WHO's DDD as reference halved the proportion of adherent patients. Adherence was higher among those using a combination inhaler of corticosteroid and long-acting β₂-agonist compared to those using steroid only inhalers. Use of WHO's daily defined doses as reference values may lead to underestimation of adherence to inhaled corticosteroids. Thus, attention should be paid when choosing the reference doses for the evaluation of adherence to inhaled corticosteroids in asthma.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"10 1","pages":"2207335"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/c3/ZECR_10_2207335.PMC10150619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9416794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the time to diagnosis and treatment influence outcome in adults with pleural infections.","authors":"Mads Brögger Klausen,&nbsp;Christian Laursen,&nbsp;Morten Bendixen,&nbsp;Babu Naidu,&nbsp;Eihab O Bedawi,&nbsp;Najib M Rahman,&nbsp;Thomas Decker Christensen","doi":"10.1080/20018525.2023.2174645","DOIUrl":"https://doi.org/10.1080/20018525.2023.2174645","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of early diagnosis and intervention in adult patients with complicated parapneumonic pleural effusion or pleural empyema and the impact on outcomes.</p><p><strong>Methods: </strong>A systematic review based on a literature search of the PubMed database was performed.</p><p><strong>Results: </strong>Eleven eligible studies were included; nine observational studies and two randomised controlled trials totalling a study population of 10,717 patients. The studies were conducted from 1992 to 2018, all in Europe and Northern America except one. Results varied between studies, but a trend towards better outcome in patients with shorter duration of symptoms and quicker initiation of treatment was found. We found that duration of symptoms before treatment may affect length of hospital stay, rate of conversion to open surgery, and frequency of complications.</p><p><strong>Conclusion: </strong>We found that an earlier intervention in adults suffering from complicated parapneumonic pleural effusion and pleural empyema may potentially improve the outcome of patients in terms of length of stay, conversion to open surgery, and general complications following treatment, but not regarding mortality. Further studies are required to specify the timing of each intervention, and direct comparison in early management of interventions.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"10 1","pages":"2174645"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/61/ZECR_10_2174645.PMC9897775.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9104513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-genome sequencing of the clinical isolate of <i>Legionella pneumophila</i> ALAW1 from the West Bank allows high-resolution typing and determination of pathogenicity mechanisms.","authors":"Ashraf R Zayed,&nbsp;Boyke Bunk,&nbsp;Lina Jaber,&nbsp;Hadeel Abu-Teer,&nbsp;Mousa Ali,&nbsp;Michael Steinert,&nbsp;Manfred G Höfle,&nbsp;Ingrid Brettar,&nbsp;Dina M Bitar","doi":"10.1080/20018525.2023.2168346","DOIUrl":"https://doi.org/10.1080/20018525.2023.2168346","url":null,"abstract":"<p><strong>Background: </strong><i>Legionella pneumophila</i> is water-based bacterium causing Legionnaires' disease (LD). We describe the first documented case of nosocomial LD caused by <i>L. pneumophila</i> sequence type (ST) 461 and serogroup 6. The etiology of LD was confirmed by culturing the bronchoalveolar lavage sample retrieving <i>L. pneumophila</i> strain ALAW1. A 7-days treatment of the LD patient with Azithromycin and Levofloxacin allowed complete recovery.</p><p><strong>Methods: </strong>In details, we sequenced the whole genome of the <i>L. pneumophila</i> ALAW1 using Illumina HiSeq platform. The sequence of ALAW1 was aligned with the genome sequence from the closely related reference strain Alcoy 2300/99 and a whole-genome phylogeny based on single nucleotide polymorphisms (SNPs) was created using Parsnp software. Also, the TYGS web-server was used in order to compare the genome with type strain.</p><p><strong>Results: </strong>An analysis of the population structure by SNP and TYGS comparison clustered ALAW1 with the reference genome Alcoy 2300/99. Blastp analysis of the type IV secretion Dot/Icm system genes showed that these genes were highly conserved with (≤25%) structural differences at the protein level.</p><p><strong>Conclusions: </strong>Overall, this study provides insights into detailed genome structure and demonstrated the value of whole-genome sequencing as the ultimate typing tool for <i>Legionella.</i></p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"10 1","pages":"2168346"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/9d/ZECR_10_2168346.PMC9869991.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10622342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The COVID-19 in athletes (COVA) study: a national study on cardio-pulmonary involvement of SARS-CoV-2 infection among elite athletes.","authors":"Hanne Kruuse Rasmusen, Mikkel Aarøe, Christoffer Valdorff Madsen, Helga Lillian Gudmundsdottir, Kenneth Hudlebusch Mertz, Astrid Duus Mikkelsen, Christian Have Dall, Christoffer Brushøj, Jesper Løvind Andersen, Maria Helena Dominguez Vall-Lamora, Ann Bovin, S Peter Magnusson, Jens Jakob Thune, Redi Pecini, Lars Pedersen","doi":"10.1080/20018525.2022.2149919","DOIUrl":"10.1080/20018525.2022.2149919","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 can cause cardiopulmonary involvement. Physical activity and cardiac complications can worsen prognosis, while pulmonary complications can reduce performance.</p><p><strong>Aims: </strong>To determine the prevalence and clinical implications of SARS-CoV-2 cardiopulmonary involvement in elite athletes.</p><p><strong>Methods: </strong>An observational study between 1 July 2020 and 30 June 2021 with the assessment of coronary biomarkers, electrocardiogram, echocardiography, Holter-monitoring, spirometry, and chest X-ray in Danish elite athletes showed that PCR-tested positive for SARS-CoV-2. The cohort consisted of male football players screened weekly (cohort I) and elite athletes on an international level only tested if they had symptoms, were near-contact, or participated in international competitions (cohort II). All athletes were categorized into two groups based on symptoms and duration of COVID-19: Group 1 had no cardiopulmonary symptoms and duration ≤7 days, and; Group 2 had cardiopulmonary symptoms or disease duration >7 days.</p><p><strong>Results: </strong>In total 121 athletes who tested positive for SARS-CoV-2 were investigated. Cardiac involvement was identified in 2/121 (2%) and pulmonary involvement in 15/121 (12%) participants. In group 1, 87 (72%), no athletes presented with signs of cardiac involvement, and 8 (7%) were diagnosed with radiological COVID-19-related findings or obstructive lung function. In group 2, 34 (28%), two had myocarditis (6%), and 8 (24%) were diagnosed with radiological COVID-19-related findings or obstructive lung function.</p><p><strong>Conclusions: </strong>These clinically-driven data show no signs of cardiac involvement among athletes who tested positive for SARS-CoV-2 infection without cardiopulmonary symptoms and duration <7 days. Athletes with cardiopulmonary symptoms or prolonged duration of COVID-19 display, exercise-limiting cardiopulmonary involvement.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"10 1","pages":"2149919"},"PeriodicalIF":1.8,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/17/ZECR_10_2149919.PMC9744211.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10730541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apical fibrobullous lung disease in ankylosing spondylitis: case report and literature review","authors":"Ana Catarina da Silva Alfaiate, Vera Maria Rêgo Durão, Joana Seabra Patrício, Maria Paula Pedrosa Silva Duarte","doi":"10.1080/20018525.2022.2086359","DOIUrl":"https://doi.org/10.1080/20018525.2022.2086359","url":null,"abstract":"ABSTRACT Ankylosing spondylitis (AS) is associated with several unique pulmonary manifestations such as apical fibrobullous disease (AFBD), which is a rare extra-spinal complication, predominantly occurring in advanced disease. Infectious complications and differential diagnosis of cavitated lung lesions may be challenging, particularly in patients already submitted to immunosuppression. In this report, we present a low body-mass-index 47-year-old male patient, ex-smoker, with AS and severe joint involvement, medicated in the past with anti-TNF-α therapy, who was diagnosed with AFBD and developed pulmonary tuberculosis and later chronic cavitary pulmonary aspergillosis. The patient died due to lung cavity major bleeding.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42280894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden","authors":"L. Lehtimäki, M. Arvidsson, B. Erdemli, C. Nan, T. Nguyen, Aditya Samant, G. Telg","doi":"10.1080/20018525.2022.2066815","DOIUrl":"https://doi.org/10.1080/20018525.2022.2066815","url":null,"abstract":"ABSTRACT Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4–5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4–5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4–5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4–5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45265088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NLC Abstracts","authors":"V. Backer, O. Hilberg, C. Ulrik","doi":"10.1080/20018525.2022.2058255","DOIUrl":"https://doi.org/10.1080/20018525.2022.2058255","url":null,"abstract":"Background: SARS-CoV-2 virus, causing Covid-19, continues to be a public health concern. Long-term sequela after infection with Covid-19 has been reported worldwide and holds the risk of becoming a major health concern. Ongoing symptoms more than 3 months after infection is now defined as long Covid. Fatigue and psychological distress are among the most common symptoms in long Covid. Aim: To investigate severe fatigue and psychological distress after hospitalization in patients with Covid-19. Methods: Patients hospitalized with Covid-19 in the Central Denmark Region were invited for follow-up 3- 6 months after discharge. Psychological distress was measured by Hospital Anxiety and Depression Scale (HADS) with a HADS score ≥8 identifying cases of anxiety and depression in the two subdomains. Fatigue was assessed using Fatigue Assessment Scale (FAS) with a FAS ≥35 indicating severe fatigue. Basic characteristics from the hospitalization were registered. Results: A total of 218 patients (mean age 59.9 (95% CI 58.2, 61.7), 59% men) reported a mean HADS of 7.9 (95% CI 6.95, 8.93). Cases of anxiety and depression were found in 23 and 16% of all patients, respectively. Overall, a mean FAS of 25.6 (95% CI 24.3, 26.9) was found with 34 patients (18%) reporting severe fatigue. Patients with severe fatigue (mean age of 54.2 (95% CI 50.3, 58.1), 47% males), cases of anxiety and depression was reported by 59 and 62%, respectively. Analyses of FAS in subdomains on mental and physical fatigue showed mean scores of 19.3 (95% CI 18.5, 20.2) and 20.6 (95% CI 19.8, 21.5), respectively. Conclusion: Severe fatigue is common after hospitalization in patients with Covid-19 and includes both mental and physical fatigue. In addition, cases of anxiety and depression are common in patients with severe fatigue.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46539073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic airway diseases: basic science, clinical manifestations and future challenges","authors":"C. Janson, L. Bjermer, L. Lehtimäki, H. Kankaanranta, J. Karjalainen, A. Altraja, V. Yasinska, B. Aarli, M. Rådinger, J. Hellgren, Magnus Lofdahl, P. Howarth, C. Porsbjerg","doi":"10.1080/20018525.2022.2040707","DOIUrl":"https://doi.org/10.1080/20018525.2022.2040707","url":null,"abstract":"ABSTRACT Eosinophils have a broad range of functions, both homeostatic and pathological, mediated through an array of cell surface receptors and specific secretory granules that promote interactions with their microenvironment. Eosinophil development, differentiation, activation, survival and recruitment are closely regulated by a number of type 2 cytokines, including interleukin (IL)-5, the key driver of eosinophilopoiesis. Evidence shows that type 2 inflammation, driven mainly by interleukin (IL)-4, IL-5 and IL-13, plays an important role in the pathophysiology of eosinophilic airway diseases, including asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Several biologic therapies have been developed to suppress type 2 inflammation, namely mepolizumab, reslizumab, benralizumab, dupilumab, omalizumab and tezepelumab. While these therapies have been associated with clinical benefits in a range of eosinophilic diseases, their development has highlighted several challenges and directions for future research. These include the need for further information on disease progression and identification of treatable traits, including clinical characteristics or biomarkers that will improve the prediction of treatment response. The Nordic countries have a long tradition of collaboration using patient registries and Nordic asthma registries provide unique opportunities to address these research questions. One example of such a registry is the NORdic Dataset for aSThmA Research (NORDSTAR), a longitudinal population-based dataset containing all 3.3 million individuals with asthma from four Nordic countries (Denmark, Finland, Norway and Sweden). Large-scale, real-world registry data such as those from Nordic countries may provide important information regarding the progression of eosinophilic asthma, in addition to clinical characteristics or biomarkers that could allow targeted treatment and ensure optimal patient outcomes.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45328241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 pneumonia pneumatoceles: a case report.","authors":"Wasim Jamal,&nbsp;Muhammad Sharif,&nbsp;Asma Sayeed,&nbsp;Saad Ur Rehman,&nbsp;Abdulqadir J Nashwan","doi":"10.1080/20018525.2022.2028423","DOIUrl":"https://doi.org/10.1080/20018525.2022.2028423","url":null,"abstract":"<p><strong>Introduction: </strong>Pneumatocele formation in COVID-19 pneumonia is arguably a common occurrence.</p><p><strong>Case presentation: </strong>We present a case of pneumatoceles, developing as a sequel of COVID-19 infection. We argue that pneumatocele formation in COVID-19 pneumonia is a common occurrence. Importantly pneumothorax, which can lead to a raised morbidity and mortality in these patients, can be a complication of a pneumatocele rupture.</p><p><strong>Conclusion: </strong>As pneumatocele in COVID-19 pneumonia patients can lead to life-threatening complications, we emphasize the need to formulate appropriate and standardized monitoring and management guidelines. Our literature review also discusses various plausible mechanisms leading to pneumatocele formation and points to management strategies that may prevent pneumatocele formation and its complications.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"9 1","pages":"2028423"},"PeriodicalIF":1.9,"publicationDate":"2022-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/a3/ZECR_9_2028423.PMC8765272.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital admission for COVID-19 pneumonitis - long-term impairment in quality of life and lung function.","authors":"Marie Vejen,&nbsp;Ejvind Frausing Hansen,&nbsp;Bakir Nabil Ibrahim Al-Jarah,&nbsp;Casper Jensen,&nbsp;Pia Thaning,&nbsp;Klaus Nielsen Jeschke,&nbsp;Charlotte Suppli Ulrik","doi":"10.1080/20018525.2021.2024735","DOIUrl":"https://doi.org/10.1080/20018525.2021.2024735","url":null,"abstract":"<p><strong>Background and aim: </strong>Knowledge of long-term consequences of severe COVID-19 pneumonitis is of outmost importance. Our aim was, therefore, to assess the long-term impact on quality of life and lung function in adults hospitalized with severe COVID-19.</p><p><strong>Methods: </strong>All patients hospitalized with COVID-19 pneumonitis at Copenhagen University Hospital-Hvidovre, Denmark, were invited to participate in the study 4-5 months after discharge. Of the 160 invited 128 responded positively (80%). Medical history and symptoms were assessed, and patients rated impact on quality of life and functional status with EuroQol-5D-5L and Post Covid Functional Scale. Lung function was assessed by dynamic spirometry and measurement of diffusing capacity.</p><p><strong>Results: </strong>Fatigue, dyspnea, cough and cognitive dysfunction were the most common symptoms. Of 128 patients, 85% had at least one symptom, and 51% reported two or more symptoms. Self-rated Quality of life was impaired assessed by EuroQol 5D-5L, with dimensions 'Pain or discomfort' (61%) and 'Usual activities' (54%) mostly affected. Functional status was significantly worse than before COVID-19 assessed by Post-COVID Functional Scale. Among lung function parameters, diffusing capacity was most affected, with 45% having diffusing capacity < 80% of predicted.</p><p><strong>Conclusion: </strong>Fatigue, respiratory symptoms and cognitive symptoms are highly common months after hospitalization for severe COVID-19. Compared to pre-COVID-19, functional status and usual activities continued to be impaired. In line with this, almost half of the patients were found to have impaired diffusing capacity.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"9 1","pages":"2024735"},"PeriodicalIF":1.9,"publicationDate":"2022-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/8c/ZECR_9_2024735.PMC8745367.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39906181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}